Eupraxia Pharmaceuticals's total assets for Q4 2025 were C$118.09M, a decrease of -8.10% from the previous quarter. EPRX total liabilities were C$7.82M for the fiscal quarter, a 43.86% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.